Underrepresentation of women in new drug trials. Ramifications and remedies

E. L. Kinney, J. Trautmann, J. A. Gold, E. S. Vesell, R. Zelis

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

Young women serve less frequently than young men as subjects in premarketing clinical drug trials. Moral, legal, and medical implications of this underrepresentation of women are considered. Risks of medical harm to female patients can increase because medication is withheld. Also, risks of toxicity increase when women receive certain new drugs only in the postmarketing phase. Remedies to increase participation of young, nonpregnant women in clinical trials are discussed.

Original languageEnglish (US)
Pages (from-to)495-499
Number of pages5
JournalUnknown Journal
Volume95
Issue number4
DOIs
StatePublished - Jan 1 1981

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint Dive into the research topics of 'Underrepresentation of women in new drug trials. Ramifications and remedies'. Together they form a unique fingerprint.

Cite this